

## DAFTAR PUSTAKA

1. Mascarella MA, Mannard E, Silva SD, Zeitouni A. Neutrophil-to-lymphocyte ratio in head and neck cancer prognosis: A systematic review and meta-analysis. *Head Neck*. 2018;40(5):1091-100.
2. Szturz P, Cristina V, Gómez RGH, Bourhis J, Simon C, Vermorken JB. Cisplatin eligibility issues and alternative regimens in locoregionally advanced head and neck cancer: Recommendations for clinical practice. *Front Oncol*. 2019;9(JUN):1-11
3. Schutte HW, Heutink F, Wellenstein DJ, et al. Impact of Time to Diagnosis and Treatment in Head and Neck Cancer: A Systematic Review. *Otolaryngology - Head and Neck Surgery (United States)*. 2020;162(4):446-57.
4. Graboyes EM, Kompelli AR, Neskey DM, et al. Association of Treatment Delays with Survival for Patients with Head and Neck Cancer: A Systematic Review. *JAMA Otolaryngol Head Neck Surg*. 2019;145(2):166-77.
5. Gratton MA, Smyth BJ. Ototoxicity of Platinum Compounds. In: Roland PS, Rutka JA, editors. *Ototoxicity*. London: Decker; 2004. p. 60–72.
6. Rybak LP, Whitworth CA. Ototoxicity: Therapeutic opportunities. *Drug Discov Today*. 2005;10(19):1313–21.
7. Gold JM, Raja A. Cisplatin (Cisplatinum). In: StatPearls. Treasure Island (FL) StatPearls Publishing; 2020. p. 1-5
8. Sturgeon J. Clinical Uses of Cisplatin. In: Rouland, Rutka, editors. *Ototoxicity*. 1st ed. London: BC Decker; 2004. p. 50–9.
9. Sheth S, Mukherjea D, Rybak LP, Ramkumar V. Mechanisms of Cisplatin-Induced Ototoxicity and Otoprotection. *Front Cell Neurosci*. 2017;11(10):1-2
10. Breglio AM, et al. The Ototoxic Chemotherapeutic Drug Cisplatin is Retained in the Human Inner Ear Indefinitely. *NIDCD National Temporal Bone, Hearing and Balance Pathology Resource Registry*. 2018;26(1):1-3
11. Scasso F, Sprio AE, Canobbio L, et al. Dietary supplementation of coenzyme Q10 plus multivitamins to hamper the ROS mediated cisplatin ototoxicity in humans: A pilot study. *Heliyon*. 2017;3(2):2-15.
12. Laksmi Putri NSPD. Perubahan Aktivitas Antioksidan Enzimatis Endogen Yang Terjadi Akibat Konsumsi Monosodium Glutamat (MSG) Berdasarkan Dosis, Waktu Paparan, dan Daerah di Jaringan Otak. *Jurnal Ilmu Kedokteran dan Kesehatan*. 2020;7(3):547-53
13. Ighodaro OM, Akinloye OA. First line defence antioxidants-superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPX): Their fundamental role in the entire antioxidant defence grid. *Alexandria Journal of Medicine*. 2018;54(4):287-93.
14. Spiro Comis by D, Rhys-evans PH, Osborne MP, Pickles JO, R Jeffries DJ, C Pearse HA. Early Morphological and Chemical Changes Induced by Cisplatin in the Guinea Pig Organ of Corti. *J Laryngol Otol*. 1986;100(12):1375-83
15. Gonçalves MS, Silveira AF, Teixeira AR, Hyppolito MA. Mechanisms of cisplatin ototoxicity: Theoretical review. *Journal of Laryngology and Otology*. 2013;127(6):536-41.

16. Rahman S, Alviandi W, Edward Y, Firdaus MA, Machmud R, Kedokteran F, et al. Gambaran audiogram nada murni penderita karsinoma kepala dan leher yang mendapat satu siklus kemoterapi Cisplatin. *Maj Kedokt Andalas*. 2000;34(1):51–9.
17. Ganesan P, Schmiedge J, Manchaiah V, Swapna S, Dhandayutham S, Kothandaraman PP. Ototoxicity: A challenge in diagnosis and treatment. *J Audiol Otol*. 2018;22(2):59–68.
18. Rybak LP. Ototoxicity. In: Wackym PA, editor. *Ballenger's Otorhinolaryngology Head and Neck Surgery*. 18th ed. Philadelphia: PMPH-USA; 2016. p. 1014–34..
19. Rybak LP, Ramkumar V. Ototoxicity. *Kidney Int*. 2007;72(8):931-5.
20. Ravi R, Somani SM, Rybak LP. Mechanism of Cisplatin Ototoxicity: Antioxidant System. *Pharmacol Toxicol*. 1995;76(6):386-94.
21. Boriskin P, Deviatkin A, Nikitin A, Pavlova O, Toropovskiy A. Relationship of catalase activity distribution in serum and tissues of small experimental animals. In: IOP Conference Series: Earth and Environmental Science. *Institute of Physics Publishing*. 2019;403(19):1-6
22. Putri Agustin M, Lisdiana. Pengaruh Paparan Rokok Elektrik Terhadap Kadar GPx Dan Catalase Pada Darah Tikus. *Life Science J*. 2021;10(1):65-75
23. Untari EK, Wahdaningsih S, Damayanti A. Efek Fraksi N-Heksana Kulit *Hylocereus Polyrhizus* Terhadap Aktivitas Katalase Tikus Stres Oksidatif. *Pharm Sci Res*. 2014;1(3):141-53
24. Gacek RR. Anatomy of the Auditory and Vestibular Systems. In: Wackym PA, Snow JB, editors. *Ballenger's Otorhinolaryngology Head and Neck Surgery*. 18th ed. Philadelphia: PMPH-USA; 2016. p. 62–108.20.
25. Gale, Jonathan. Forge A. Anatomy Of The Cochlea And Vestibular System: Relating Ultrastructure To Function. In: scott-brown's otorhinolaryngology head and neck surgery. 8th Edition. 2019. p. 545–64.
26. Maria, PL. Oghalai J. Anatomy and Physiology of the Auditory System. In: Sataloff R, editor. *Sataloff's Comprehensive Textbook of Otolaryngology Head and Neck Surgery Otology/Neurotology/Skull Base Surgery*. Jaypee: The Health Sciences Publisher; 2016. p. 1–18.
27. Driver EC, Kelley MW. Development of the cochlea. *Development (Cambridge)*. 2020;147(12):1-13
28. Nisa NA, Reza M, Yetti I. Pengaruh Kebisingan Terhadap Kadar Malondialdehyd dan Kecepatan Spermatozoa Tikus *Rattus Norvegicus* Jantan. *WK-JIJK*. 2020;6(2):51–8.
29. Dasgupta S MM. Physiology of Hearing. In: Watkinson JC CR, editor. *Scott Brown's Otorhinolaryngology Head and Neck Surgery 2nd Ed. 8th Ed*. London: Taylor & Francis Group; 2018. p. 567–89.
30. Nyberg S, Joan Abbott N, Shi X, Steyger PS, Dabdoub A. Delivery of therapeutics to the inner ear: The challenge of the blood-labyrinth barrier. *Sci Transl Med*. 2019;11(482).
31. Dhingra P, Dhingra S. Diseases of Ear, Nose and Throat & Head and Neck Surgery. 7th ed. Dhingra P, Dhingra S, editors. New Delhi: Elsevier; 2018. p. 1–529
32. Dhingra P DS. Diseases of Ear. In: Dhingra P DS, editor. *Diseases of Ear, Nose and Throat & Head and Neck Surgery. 7th Ed*. New Delhi: Elsevier; 2018. p. 3–145.

33. Sarreal RR, Bhatti P. Characterization and miniaturization of silver-nanoparticle microcoil via aerosol jet printing techniques for micromagnetic cochlear stimulation. *Sensors (Switzerland)*. 2020;20(21):1-13.
34. Joo Y, Cruickshanks KJ, Klein BEK, Klein R, Hong O, Wallhagen M. Prevalence of ototoxic medication use among older adults in Beaver Dam, Wisconsin. *J Am Assoc Nurse Pract*. 2018;30(1):27-34.
35. Rahmawati I, Isbaniah F, Agustin H, Sarikencana RE. Prevalens Ototoksik pada Pasien Tuberkulosis Resistan Obat dan Faktor-Faktor yang Berhubungan di Rumah Sakit Umum Pusat Persahabatan. *J Respirologi Indonesia*. 2019;39(3):180–95.
36. Rybak LP. Vestibular and Auditory Ototoxicity. In: Flint PW, Robbins KT, Francis HW, Lesperance MM, Haughey BH, Lund VJ, editors. *Cummings Otolaryngology Head and Neck Surgery*. 7th editio. Philadelphia: Elsevier; 2021. p. 2370–80.
37. Ganesan P, Schmiedge J, Manchaiah V, Swapna S, Dhandayutham S, Kothandaraman PP. Ototoxicity: A Challenge in Diagnosis and Treatment. *J Audiol Otol*. 2018;22(2):59-68.
38. Watts KL. Ototoxicity: Visualized in Concept Maps. *Semin Hear*. 2019;40(2):177-87.
39. Forge A. Ototoxicity. In: Watkinson JC, Clarke RW, editors. *Scott-Brown's Otorhinolaryngology: Head and Neck Surgery* 8Ed. 2nd ed. London: Taylor & Francis Group; 2018. p. 721–33.
40. Alderden RA, Hall MD, Hambley TW. The discovery and development of cisplatin. *J Chem Educ*. 2006;83(5):728-34.
41. Landier W. Ototoxicity and cancer therapy. *Cancer*. 2016;122(11):1647-58.
42. Soares F, Patatt A, Gonc LF, Haas P, Paiva KM De. Ototoxic effects of antineoplastic drugs : a systematic review. *Braz J Otorhinolaryngol*. 2022;88(1):130-40.
43. Tserga E, Nandwani T, Edvall NK, et al. The genetic vulnerability to cisplatin ototoxicity : a systematic review. *Sci Rep*. 2019;9(3455):1-12.
44. Putri MH, Rahaju P, Indrasworo D. Hubungan ototoksisitas dan kemoterapi neoadjuvan pada karsinoma nasofaring berdasarkan ASHA, CTCAE, dan DPOAE. *Oto Rhino Laryngologica Indonesiana*. 2018;47(2):102.
45. Tilova MM. Pengaruh Terapi Cisplatin Dan Paclitaxel Dengan Dan Tanpa Pemberian Ginkgo Biloba Terhadap Ambang Dengar Dan Fungsi Sel Rambut Luar Koklea Penderita Karsinoma Nasofaring. *Thesis Universitas Hassanudin*. 2021. p. 1-84
46. Rybak LP, Mukherjea D, Jajoo S, Ramkumar V. Cisplatin Ototoxicity and Protection: Clinical and Experimental Studies. *Tohoku J Exp Med*. 2009. 219(3):177-86.
47. Paken J, Govender CD, Pillay M, Sewram V. Cisplatin-Associated Ototoxicity: A Review for the Health Professional. *J Toxicol*. 2016;2016(NOV):1-13.
48. Fang B, Xiao H. Rapamycin alleviates cisplatin-induced ototoxicity in vivo. *Biochem Biophys Res Commun*. 2014;448(4):443-47.
49. Tan M, Toplu Y, Varan E, et al. The effect of genistein on cisplatin induced ototoxicity and oxidative stress. *Braz J Otorhinolaryngol*. 2022;88(1):105-11.
50. Mas-Bargues C, Escrivá C, Dromant M, Borrás C, Viña J. Lipid peroxidation as measured by chromatographic determination of malondialdehyde. Human plasma reference values in health and disease. *Arch Biochem Biophys*. 2021;709(JUN):2-7
51. Iga Maharani A, Riskierdi F, et al. Peran Antioksidan Alami Berbahan Dasar Pangan Lokal dalam Mencegah Efek Radikal Bebas. *Prosiding SEMNAS BIO 2021 Universitas Negeri Padang*. 2021;1(APR):390-9

52. Adi Parwata, IMO, Antioxidant. In : Buku Ajar Kimia Terapan ed:1. Universitas Udayana. 2016. p. 13-36.
53. Majumder P, Duchon MR, Gale JE. Cellular glutathione content in the organ of corti and its role during ototoxicity. *Front Cell Neurosci.* 2015;9(APR):1-8
54. Sonthalia S, Daulatabad D, Sarkar R. Glutathione as a skin whitening agent: Facts, myths, evidence and controversies. *Indian J Dermatol Venereol Leprol.* 2016;82(3):262-72.
55. Pak JH, Kim Y, Yi J, Chung JW. Antioxidant therapy against oxidative damage of the inner ear: Protection and preconditioning. *Antioxidants.* 2020;9(11):1-21.
56. Crundwell G, Gomersall P, Baguley DM. Ototoxicity (cochleotoxicity) classifications: A review. *Int J Audiol.* 2016;55(2):65-74.
57. Bennett KOC, Dille MF. National Guidelines for Ototoxicity Monitoring in Adult Patients: Perspectives on Patient Populations, Service Gaps, Barriers and Solutions. *Int J Audiol.* 2019;57:1-30.
58. Durrant JD, Campbell K, Fausti S, Guthrie OW, Jacobson G, Lonsbury-Martin BL et al. American Academy of Audiology Position Statement and Clinical Practice Guidelines Ototoxicity Monitoring. *American Academy of Audiology Position Statement.* 2009;(October):1-25.
59. Al-malky G. Audiological monitoring in ototoxicity. *ENT and Audiology News.* 2016;25(5):1-3.
60. Dahlan MS. Menentukan Besar Sampel. In: Susila A, editor. Besar Sampel dan Cara Pengambilan Sampel Dalam Penelitian Kedokteran dan Kesehatan. 3rd ed. Jakarta: Salemba Medika; 2010.p.19-23.
61. Anggraeni R, Darmawan A, F FW. The Association of Glutathion Peroxydase - 1 Serum and Sensorineural Hearing Lossin MDR TB Patients with Kanamycin Therapy. *Indian J Public Heal Res.* 2020;11(01):1102-7.
62. Kawakita D, Oze I, Iwasaki S, Matsuda T, Matsuo K, Ito H. Trends in the incidence of head and neck cancer by subsite between 1993 and 2015 in Japan. *Cancer Med.* 2022.1;11(6):1553-60.
63. Saputra R. Pengaruh Injeksi N-Asetilsistein Intratimpani sebagai Otoproteksi Terhadap Ambang Dengar Penderita Tumor Kepala Leher yang Mendapat Kemoterapi Cisplatin. Universitas Andalas; 2023.
64. Nathania N, Dewi YA, Permana AD. Profile of head neck cancer patients from 2013-2018 at Dr. Hasan Sadikin General Hospital Bandung. *ORLI.* 2020;51(2):141-5.
65. Faiza, Shofi. Rahman, Sukri. Asri A. Karakteristik Klinis dan Patologis Karsinoma Nasofaring di Bagian THT-KL RSUP Dr. M. Djamil Padang. *Jurnal Kesehatan Andalas.* 2016;5(1):90-6.
66. Mion O, Andrade N. Oral Cancer: Population Sample of the State of Alagoas at a Reference Hospital. *Braz J Otorhinolaryngol.* 2009;75(4):471.
67. Munir M. Keganasan di Bidang Telinga Hidung Tenggorok. In: Soepardi, editor. Buku Ajar Ilmu Kesehatan Telinga Hidung Tenggorok Kepala dan Leher. 7th ed. Jakarta: Balai Penerbit FKUI; 2007. p.132.
68. Syah M, Sabirin M, Permana AD, Soeseno B. Epidemiologi Penderita Tumor Ganas Kepala Leher di Departemen Telinga Hidung Tenggorokan - Kepala Leher Rumah Sakit Dr. Hasan Sadikin Bandung, Indonesia, Periode 2010 - 2014. *Jurnal Universitas Padjajaran.* 2014;1(1):21-28

69. José Cabral Ruback MI, Livia Galbiatti AI, Maria Rebolho Batista Arantes LI, Henrique Marucci GI, Russo AI, Torreglosa Ruiz-Cintra MI, et al. Clinical and epidemiological characteristics of patients in the head and neck surgery department of a university hospital. *Sao Paulo Med J.* 2012;130(5): 307-13.
70. Obaidul Islam M, Bacchetti TT, Ferretti G. Alterations of Antioxidant Enzymes and Biomarkers of Nitro-oxidative Stress in Tissues of Bladder Cancer. *Oxid Med Cell Longev.* 2019;201(3):45-75.
71. Cecerska-Heryć E, Surowska O, Heryć R, Serwin N, Napiontek-Balińska S, Dołęgowska B. Are antioxidant enzymes essential markers in the diagnosis and monitoring of cancer patients – A review. *Clin Biochem.* 2021;93:1-8.
72. Marjaneh RM, Rahmani F, Hassanian SM, et al. Phytosomal curcumin inhibits tumor growth in colitis-associated colorectal cancer. *J Cell Physiol.* 2018;233(10):6785-98.
73. Zalewska-Ziob M, Adamek B, Kasperczyk J, et al. Activity of Antioxidant Enzymes in the Tumor and Adjacent Noncancerous Tissues of Non-Small-Cell Lung Cancer. *Oxid Med Cell Longev.* 2019;19(7):745-57.
74. Pratibha R, Sameer R, Rataboli P V, Bhiwgade DA, Dhume CY. Enzymatic studies of cisplatin induced oxidative stress in hepatic tissue of rats. Elsevier. 2006;532:290–3.
75. Yousif SW, Taqa GA, Taha AM. The Effects of Melatonin on Caspase-3 and Antioxidant Enzymes Activity in Rats Exposed to Anticancer Drug. *Egypt J Chem.* 2023;66(2):283-9.
76. Utama DS, Eriza, Priscilla Ralahayu, Erial Bahar. Relationship between Primary Tumors of Nasopharyngeal Carcinoma with the Degree of Conductive Hearing Loss in Dr. Mohammad Hoesin Hospital Palembang. *Bioscientia Medicina: Journal of Biomedicine and Translational Research.* 2022;6(3):1423–34.
77. Cahyadi I, Dewi YA. Status Pendengaran pada Penderita Karsinoma Nasofaring. 2014;23(2):1-7
78. Schuette A, Lander DP, Kallogjeri D, Collopy C, Goddu S, Wildes TM, et al. Predicting Hearing Loss after Radiotherapy and Cisplatin Chemotherapy in Patients with Head and Neck Cancer. *JAMA Otolaryngol Head Neck Surg.* 2020;146(2):106–12.
79. Toplu Y, Parlakpınar H, Sapmaz E, Karatas E, Polat A, Kizilay A. The Protective Role of Molsidomine on the Cisplatin-Induced Ototoxicity. *Indian Journal of Otolaryngology and Head and Neck Surgery.* 2014;66(3):314-319.
80. Rezaeyan AH, Ghaffari H, Mahdavi SR, Nikoofar AR, Najafi M, Koosha F, et al. Audiometric findings in patients with head and neck chemoradiotherapy and radiotherapy: Short-term outcomes. *International Journal of Radiation Research.* 2019;17(4):633–41.
81. Haugnes HS, Stenklev NC, Brydøy M, Dahl O, Wilsgaard T, Laukli E, et al. Hearing loss before and after cisplatin-based chemotherapy in testicular cancer survivors: a longitudinal study. *Acta Oncol (Madr).* 2018;57(8):1075–83.
82. Arora R, Thakur JS, Azad RK, Mohindroo NK, Sharma DR, Seam RK. Cisplatin-based chemotherapy: Add high-frequency audiometry in the regimen. *Indian J Cancer.* 2009;46(4):311.
83. Widayati, E. Oksidasi Biologi, Radikal Bebas, dan Antioxidant. *Majalah Ilmiah Sultan Agung.* 2023; 50(128): 26-32.

84. Toplu Y, Kizilay A, Sapmaz E, et al. The effect of dexpanthenol on ototoxicity induced by cisplatin. *Clin Exp Otorhinolaryngol.* 2016;9(1):14-20.

